JSM2026
Back to the program
Topic-Contributed Paper Session

Current methodology advances and practice in oncology dose optimization studies

Wed, Aug 5, 8:30 AM - 10:20 AM Room CC-206A Thomas M. Menino Convention & Exhibition Center
Patrick MitchellOrganizerRevathi AnanthakrishnanOrganizerPatrick MitchellChair
Biopharmaceutical Section co: International Indian Statistical Associationco: Biometrics Section Applied

5 Presentations

Dose optimization strategies and practice based on the industry survey and dose optimization whitepaper from a KOL panel discussion
8:35 AM - 8:55 AM
Philip He (Daiichi Sankyo Inc.)
Co-authors: Philip He (Daiichi Sankyo Inc.), Revathi Ananthakrishnan (Bristol-Myers Squibb), Patrick Mitchell, Gina D'Angelo (AstraZeneca), Haijun Ma, Dong Xi (Gilead Sciences), Gu Mi (Sanofi), Yujun Wu (Morphic Therapeutic), Ying Yuan (University of Texas MD Anderson Cancer Center)
dose optimizationProject Optimus
Group Sequential Testing in Phase 2/3 Oncology Trials with dose selection based on an early endpoint
8:55 AM - 9:15 AM
Yuxuan Chen (Daiichi Sankyo, Inc)
Co-authors: Haiming Zhou (Daiichi Sankyo, Inc.), Philip He (Daiichi Sankyo Inc.)
Oncology;Dose optimization;Seamless phase 2/3;Group-sequential testing;P-value combination;Multiplicity adjustment
Novel adaptive factorial designs for evaluating contributions of components for combination therapies
9:15 AM - 9:35 AM
Ruitao Lin (University of Texas, MD Anderson Cancer Center)
Co-authors: Ruitao Lin (University of Texas, MD Anderson Cancer Center)
Clinical TrialsBayesian DesignAdaptive DesignDrug CombinationOncologyDose Optimization
The Reversed Multi-Arm Two-Stage (RevMATS) Design in Oncology Dose Optimization
9:35 AM - 9:55 AM
Gu Mi (Sanofi)
Co-authors: Gu Mi (Sanofi), Yue Yang (North Carolina State University), Ji Lin (Sanofi)
Bayesian adaptive designDose optimizationOncologyProject Optimus
Utility-Based Dose Optimization Approaches for Multiple-Dose Randomized Trial Designs Accounting for Multiple Endpoints
9:55 AM - 10:15 AM
Gina D'Angelo (AstraZeneca)
Co-authors: Gina D'Angelo (AstraZeneca)
dose optimizationutilityrandomized dosesmultiple endpoints
↑